STRO Key Statistics, Chart & Performance
The current stock price of STRO is 14.57 USD. In the past month the price increased by 29.25%. In the past year, price decreased by -25.18%.
STRO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to STRO. When comparing the yearly performance of all stocks, STRO is one of the better performing stocks in the market, outperforming 86.47% of all stocks.
STRO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to STRO. STRO has a bad profitability rating. Also its financial health evaluation is rather negative.
STRO Financial Highlights
Over the last trailing twelve months STRO reported a non-GAAP Earnings per Share(EPS) of -26.1. The EPS decreased by -62.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
STRO Forecast & Estimates
16 analysts have analysed STRO and the average price target is 34.53 USD. This implies a price increase of 137.02% is expected in the next year compared to the current price of 14.57.
For the next year, analysts expect an EPS growth of 26.01% and a revenue growth 68.12% for STRO
STRO Ownership
STRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.97 | 383.716B | ||
| AMGN | AMGEN INC | 16.3 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.77 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.83 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.6 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.14 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.09 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.46 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STRO
Company Profile
Sutro Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 178 full-time employees. The company went IPO on 2018-09-27. Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Company Info
SUTRO BIOPHARMA INC
111 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: William J. Newell
Employees: 310
Phone: 16503928412
SUTRO BIOPHARMA INC / STRO FAQ
What does SUTRO BIOPHARMA INC do?
Sutro Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 178 full-time employees. The company went IPO on 2018-09-27. Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
What is the current price of STRO stock?
The current stock price of STRO is 14.57 USD. The price decreased by -2.15% in the last trading session.
What is the dividend status of SUTRO BIOPHARMA INC?
STRO does not pay a dividend.
How is the ChartMill rating for SUTRO BIOPHARMA INC?
STRO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy STRO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on STRO.
What is the employee count for STRO stock?
SUTRO BIOPHARMA INC (STRO) currently has 310 employees.
Can you provide the ownership details for STRO stock?
You can find the ownership structure of SUTRO BIOPHARMA INC (STRO) on the Ownership tab.